SNY logo

SNYSanofi-Aventis

$43.57
$1.16
(2.59%)
Today
Closed $43.57
$0.01
(0.02%)
After Hours
Updated: 07:09 PM EDT
EarningsJul 30
Mkt Cap$104.75B
Vol4.03M
News
all
press releases
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.
Zacks
News Placeholder
More News
News Placeholder
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.
Zacks
News Placeholder
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Zacks
News Placeholder
Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector
(RTTNews) - The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications for Sarclisa intravenous (IV) formulation, Sanofi SA (SN...
Nasdaq News: Markets
News Placeholder
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.read more...
Benzinga
News Placeholder
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.
Zacks
News Placeholder
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
Zacks
News Placeholder
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Zacks
News Placeholder
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.
Zacks
News Placeholder
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
Zacks
<
1
2
...
>

Advertisement|Remove ads.